CAR-T Cell Therapy – Frederick Locke, MD, and Robert Figlin, MD, discuss clinical highlights from ASH 2018

CAR-T Cell Therapy – Frederick Locke, MD, and Robert Figlin, MD, discuss clinical highlights from ASH 2018

Wednesday December 19, 2018

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Frederick Locke, MD, Program Co-Leader, Immunology, Moffitt Cancer Center discuss CAR-T clinical highlights from ASH 2018

Non Small Cell Lung Cancer (NSCLC) – Edward Garon, MD, and Robert Figlin, MD, discuss promising agents in development for the management of NSCLC from ASCO20

Thursday June 11, 2020

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center, and Edward Garon, MD, Director of Thoracic Oncology Program, Jonsson Comprehensive Cancer Center, Associate Professor of Medicine, David Geffen School of Medicine, UCLA, discuss promising agents in development for the management of NSCLC from ASCO20

Waldenstrom macroglobulinemia – Constantine Tam, MD, and Robert Figlin, MD, discuss recent clinical advances in the treatment of Waldenstrom macroglobulinemia from ASCO20

Monday June 8, 2020

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center, and Constantine Tam, MD, Haematologist and Disease Group Lead, Low Grade Lymphoma and Chronic Lymphocytic Leukemia, Peter MacCallum Cancer Centre, discuss the progress in Waldenstrom macroglobulinemia from ASCO20

Featured Videos

Debu Tripathy, MD, introduces new information onCDK4/6 inhibitors discussed at ASCO20

Shaji Kumar, MD, provides perspective on the role of anti-CD38 antibodies changing multiple myeloma

Dana Chase, MD, FACOG, on interpretations of the overall survival results of the Phase 3 SOLO2 study